Summary
Global Markets Direct’s, ‘Merck & Co., Inc. - Product Pipeline Review - 2016’, provides an overview of the Merck & Co., Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc.
- The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Merck & Co., Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Merck & Co., Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Merck & Co., Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Merck & Co., Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Merck & Co., Inc. Snapshot 8
Merck & Co., Inc. Overview 8
Key Information 8
Key Facts 8
Merck & Co., Inc. - Research and Development Overview 9
Key Therapeutic Areas 9
Merck & Co., Inc. - Pipeline Review 21
Pipeline Products by Stage of Development 21
Pipeline Products - Monotherapy 22
Pipeline Products - Combination Treatment Modalities 23
Pipeline Products - Partnered Products 24
Pipeline Products - Out-Licensed Products 28
Merck & Co., Inc. - Pipeline Products Glance 31
Merck & Co., Inc. - Late Stage Pipeline Products 31
Merck & Co., Inc. - Clinical Stage Pipeline Products 34
Merck & Co., Inc. - Early Stage Pipeline Products 38
Merck & Co., Inc. - Drug Profiles 42
(elbasvir + grazoprevir) 42
asenapine maleate 44
bezlotoxumab 45
desloratadine 46
diquafosol tetrasodium 48
fosaprepitant dimeglumine 50
insulin glargine 51
narlaprevir 53
pembrolizumab 54
(actoxumab + bezlotoxumab) 64
(atorvastatin calcium + ezetimibe) 65
(ceftolozane sulfate + tazobactam sodium) 66
(cilastatin sodium + imipenem + relebactam) 68
(doravirine + lamivudine + tenofovir disoproxil fumarate) 69
actoxumab 70
anacetrapib 71
corifollitropin alfa 73
doravirine 75
fidaxomicin 77
letermovir 81
odanacatib 82
omarigliptin 84
posaconazole 86
solithromycin 87
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract 90
tedizolid phosphate 93
V-212 96
V-920 98
verubecestat 101
vibegron 102
vorinostat 103
(grazoprevir + MK-3682 + MK-8408) 107
BQ-123 108
dalotuzumab 110
elbasvir + grazoprevir + MK-3682 113
grazoprevir 114
lomerizine 116
lonafarnib 117
mirtazapine ODT 119
MK-1029 120
MK-2206 121
MK-2206 + selumetinib sulfate 124
MK-7622 126
MK-8521 127
MK-8628 128
samatasvir 130
temozolomide 132
V-114 134
MK-3682 135
vorapaxar sulfate 137
CB-618 139
insulin human 140
MK-0752 141
MK-1075 143
MK-1248 144
MK-2048 145
MK-2248 146
MK-4166 147
MK-7680 148
MK-8189 149
MK-8242 150
MK-8291 152
MK-8408 153
MK-8507 154
MK-8591 155
MK-8666 156
MK-8723 157
MK-8876 158
Monoclonal Antibody for Autoimmune Diseases 159
NB-1008 160
rituximab biosimilar 161
Small Molecule 1 for Human Cytomegalovirus Infection 162
Small Molecule 2 for Human Cytomegalovirus Infection 163
V-160 164
V-180 165
BNC-375 167
CB-027 168
chikungunya (viral like particles) vaccine 169
DORA-12 170
Drug to Inhibit 11Beta-HSD1 for Hypertension 171
ETP-142 172
GP-4 173
GRA-1 175
J8-CRM197 176
mDX-400 177
MK-0429 178
MK-1966 179
MK-4256 180
MK-8267 181
MK-8745 182
MK-8825 183
MK-8970 184
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 185
Monoclonal Antibody for Cancer 186
MRK-003 187
MRK-1777 188
MRLB-11055 189
Proteins for Cancer, Autoimmune and Inflammatory diseases 190
PTC-512 191
PTC-725 192
PTC-971 193
PyP-1 194
respiratory syncytial virus vaccine 195
SCH-412348 196
SCH-546738 197
Small Molecule 3 for Human Cytomegalovirus Infection 198
Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 199
Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes 200
Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection 201
Small Molecule to Inhibit ROMK for Hypertension and Heart Failure 202
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis 203
Small Molecules for Undisclosed Indications 204
Small Molecules to Agonize GPR119 for Metabolic Disorders 205
Small Molecules to Agonize M1 for Alzheimer’s Disease 206
Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 208
Small Molecules to Block Cav2.2 Channel for Chronic Pain 209
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases 210
Small Molecules to Inhibit DGAT1 211
Small Molecules to Inhibit DHFR for Septicaemia 212
Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours 213
Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 214
Small Molecules to Inhibit Renin for Hypertension 215
THPP-1 216
TROX-1 217
XEN-445 218
XL-499 219
Drug to Target GPCR for Undisclosed Indication 220
Kibdelomycin A 221
MK-8133 222
Monoclonal Antibodies for Undisclosed Indication 223
Monoclonal Antibody for Neurology 224
SCH-722984 225
Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication 226
Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections 227
Small Molecules to Inhibit IRAK4 for Inflammatory Diseases 228
Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation 229
Small Molecules to Inhibit NS5A for Hepatitis C 230
Small Molecules to Inhibit PPI for Undisclosed Indication 231
Undisclosed Biosimilars 233
Merck & Co., Inc. - Pipeline Analysis 234
Merck & Co., Inc. - Pipeline Products by Target 234
Merck & Co., Inc. - Pipeline Products by Route of Administration 240
Merck & Co., Inc. - Pipeline Products by Molecule Type 242
Merck & Co., Inc. - Pipeline Products by Mechanism of Action 243
Merck & Co., Inc. - Recent Pipeline Updates 248
Merck & Co., Inc. - Dormant Projects 323
Merck & Co., Inc. - Discontinued Pipeline Products 331
Discontinued Pipeline Product Profiles 333
Merck & Co., Inc. - Company Statement 343
Merck & Co., Inc. - Locations And Subsidiaries 345
Head Office 345
Other Locations & Subsidiaries 345
Appendix 376
Methodology 376
Coverage 376
Secondary Research 376
Primary Research 376
Expert Panel Validation 376
Contact Us 376
Disclaimer 377
List of Tables
Merck & Co., Inc., Key Information 19
Merck & Co., Inc., Key Facts 19
Merck & Co., Inc. - Pipeline by Indication, 2016 21
Merck & Co., Inc. - Pipeline by Stage of Development, 2016 32
Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016 33
Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016 34
Merck & Co., Inc. - Partnered Products in Pipeline, 2016 35
Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2016 36
Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016 39
Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 40
Merck & Co., Inc. - Pre-Registration, 2016 42
Merck & Co., Inc. - Phase III, 2016 43
Merck & Co., Inc. - Phase II, 2016 45
Merck & Co., Inc. - Phase I, 2016 47
Merck & Co., Inc. - Preclinical, 2016 49
Merck & Co., Inc. - Discovery, 2016 52
Merck & Co., Inc. - Pipeline by Target, 2016 245
Merck & Co., Inc. - Pipeline by Route of Administration, 2016 252
Merck & Co., Inc. - Pipeline by Molecule Type, 2016 253
Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2016 254
Merck & Co., Inc. - Recent Pipeline Updates, 2016 259
Merck & Co., Inc. - Dormant Developmental Projects,2016 334
Merck & Co., Inc. - Discontinued Pipeline Products, 2016 342
Merck & Co., Inc., Subsidiaries 356
List of Figures
Merck & Co., Inc. - Pipeline by Top 10 Indication, 2016 21
Merck & Co., Inc. - Pipeline by Stage of Development, 2016 32
Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016 33
Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016 34
Merck & Co., Inc. - Partnered Products in Pipeline, 2016 35
Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016 39
Merck & Co., Inc. - Pipeline by Top 10 Target, 2016 245
Merck & Co., Inc. - Pipeline by Top 10 Route of Administration, 2016 251
Merck & Co., Inc. - Pipeline by Top 10 Molecule Type, 2016 253
Merck & Co., Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 254
